Barclays upgrades Schott Pharma on growth inflection; shares jump
Investing.com -- Barclays upgraded Schott Pharma to Overweight, pointing to an inflection point after three years of earnings downgrades at the pharmaceutical packaging maker, sending its shares rising more than 4% in early Frankfurt trading. The brokerage said it expects growth to accelerate on the back of renegotiated contracts, improving polymer demand, and growth in ready-to-use and specialty vials.
Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓
Investing.com -- Barclays upgraded Schott Pharma to Overweight, pointing to an inflection point after three years of earnings downgrades at the pharmaceutical packaging maker, sending its shares rising more than 4% in early Frankfurt trading. The brokerage said it expects growth to accelerate on the back of renegotiated contracts, improving polymer demand, and growth in ready-to-use and specialty vials. Barclays forecasts earnings per share 6% ahead of consensus estimates for 2028. Since Schott Pharma’s 2023 listing, consensus earnings estimates have been repeatedly revised lower, driven by destocking and overcapacity in the vials market, weaker glass pre-filled syringe (PFS) orders, and a slowdown in polymer demand.
Read the full report at Investing.com · Stock Market ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Investing.com -- Barclays upgraded Schott Pharma to Overweight, pointing to an inflection point after three years of earnings downgrades at the pharmaceutical packaging maker, sending its shares rising more than 4% in early Frankfurt trading. The brokerage said it expects growth to accelerate on the back of renegotiated contracts, improving polymer demand, and growth in ready-to-use and specialty vials.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 14m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Barclays upgrades Schott Pharma on growth inflection; shares jump
Sources1TypeCoverageInvesting.com · Stock Market